Non-superiority of zuranolone (SAGE-217) at the longer-term

Affiliations

¹ Department of Psychiatry, Rijnstate hospital, Arnhem, the Netherlands; Amsterdam UMC, University of Amsterdam, Department of Psychiatry, Amsterdam Neuroscience, Amsterdam, the Netherlands.
² Department of Psychiatry, Rijnstate hospital, Arnhem, the Netherlands.
³ Amsterdam UMC, University of Amsterdam, Department of Psychiatry, Amsterdam Neuroscience, Amsterdam, the Netherlands; Amsterdam Brain and Cognition, University of Amsterdam, the Netherlands. Electronic address: g.a.vanwingen@amsterdamumc.nl.

Comment

F Ten Doesschate et al. J Affect Disord. 2021.

. 2021 Aug 1:291:329-330.

doi: 10.1016/j.jad.2021.05.015. Epub 2021 May 23.

¹ Department of Psychiatry, Rijnstate hospital, Arnhem, the Netherlands; Amsterdam UMC, University of Amsterdam, Department of Psychiatry, Amsterdam Neuroscience, Amsterdam, the Netherlands.
² Department of Psychiatry, Rijnstate hospital, Arnhem, the Netherlands.
³ Amsterdam UMC, University of Amsterdam, Department of Psychiatry, Amsterdam Neuroscience, Amsterdam, the Netherlands; Amsterdam Brain and Cognition, University of Amsterdam, the Netherlands. Electronic address: g.a.vanwingen@amsterdamumc.nl.

No abstract available

Comment in

Zuranolone provides a rapid response without chronic dosing: Response to correspondence by ten Doesschate et al.
Arnaud A, Bonthapally V. Arnaud A, et al. J Affect Disord. 2022 Mar 15;301:445-447. doi: 10.1016/j.jad.2022.01.059. Epub 2022 Jan 13. J Affect Disord. 2022. PMID: 35032505 No abstract available.
Still no evidence for the efficacy of zuranolone beyond two weeks: Response to Arnaud and Bonthapally.
Ten Doesschate F, van Waarde JA, van Wingen GA. Ten Doesschate F, et al. J Affect Disord. 2022 Sep 15;313:149-150. doi: 10.1016/j.jad.2022.06.085. Epub 2022 Jun 30. J Affect Disord. 2022. PMID: 35780962 No abstract available.

Number Needed to Treat and Number Needed to Harm analysis of the zuranolone phase 2 clinical trial results in major depressive disorder.
Arnaud A, Suthoff E, Stenson K, Werneburg B, Hodgkins P, Bonthapally V, Jonas J, Meyer K, O'Day K. Arnaud A, et al. J Affect Disord. 2021 Apr 15;285:112-119. doi: 10.1016/j.jad.2021.02.027. Epub 2021 Feb 10. J Affect Disord. 2021. PMID: 33640861